{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009366","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.132311+00:00","generated_at":"2026-06-25T20:53:47.644318+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Clearside Biomedical Q1 2022 net loss $7.6M; CLS-AX cohort 4 enrolling","bullets":["Net loss of $7.6M ($0.13 per share) vs $7.4M ($0.13) in Q1 2021; revenue $347K vs $34K.","Cash and equivalents $34.4M; company expects sufficient for at least next 12 months.","XIPERE (suprachoroidal triamcinolone) commercially launched in U.S. by Bausch + Lomb for uveitic macular edema.","CLS-AX Phase 1/2a OASIS trial: Cohort 4 enrolling at 1.0 mg; no dose-limiting toxicities in Cohort 3; safety data expected Q4 2022.","Benjamin R. Yerxa appointed to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009366","json":"https://secwatch.observer/filing/0000950170-22-009366.json","markdown":"https://secwatch.observer/filing/0000950170-22-009366.md","text":"https://secwatch.observer/filing/0000950170-22-009366.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022009366/0000950170-22-009366-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022009366/clsd-20220511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T20:53:47.644318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}